Forbes Medi-Tech fka FMTI

[jmurfk]

Delisted from NASDAQ to OTC for not maintaining the $1.00 PPS requirement. Last 10K shows .03 EPS. Nice entry level here IMO.

[Bigatin]

NEWS

Mon Oct 26, 2009
Forbes Medi-Tech cholesterol lowering ingredient Reducol(tm) receives new health claim in the European Union
VANCOUVER, BC -- Forbes Medi-Tech Inc. (NASDAQ:FMTI) ("Forbes" or "Company") Forbes Medi-Tech today announced that the European Union ("EU") has approved a health claim for plant sterols in free or esterified form.

This recent Commission Regulation will enable products that incorporate Forbes patented cholesterol lowering ingredient, Reducol(tm), to make a label claim that states "Plant sterols have been shown to lower/reduce cholesterol. High cholesterol is a risk factor in the development of coronary artery disease".

The EU Commission Decision, 2004/845/EC which authorized the use of Reducol(tm) in Novel Foods in the EU was included in the EFSA Opinion Q-2008-085, which recommended approval of the claim.

"The approval extends Forbes current cholesterol reduction claim and further validates the inclusion of Reducol(tm) in various food products "said Dr. David Stewart, VP Regulatory & Scientific Affairs at Forbes.

Reducol(tm) is sold in various food products in the EU including margarine, yoghurts, yoghurt drinks, milk, and cheese.

About Forbes Medi-Tech
Forbes Medi-Tech Inc. (NASDAQ:FMTI) is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol(tm) plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower "LDL" cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products. For more information about Forbes Medi-Tech, please visit www.forbesmedi.com.

Reducol(tm) is a trademark of Forbes Medi-Tech Inc.

Forward looking Statements and Risks
This News Release contains forward-looking statements regarding opportunities for Reducol(tm) in Europe and future product launches. Forward looking statements can be identified by the use of forward-looking terminology such as "to make", "will enable", or any other variations thereon or comparable terminology referring to future dates, events or results. Forward-looking statements are statements about the future and are inherently uncertain, and the Company's actual results could differ materially from those anticipated in those forward-looking statements as a result of numerous factors, including without limitation; uncertainty of the size and existence of a market opportunity for the Company's and its customers' products; uncertainty whether planned product launches will occur as planned; uncertainty regarding market acceptance of the Company's and its customers' products; performance by the Company's customers; product liability and insurance risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; exchange rate fluctuations; the Company's need for additional future capital, which may not be available in a timely manner or at all; intellectual property risks; environmental risks. Such risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest Annual Report on Form 20-F, and latest MD&A and other reports, filed with the Canadian Securities Regulatory Authorities from time to time at www.sedar.com, and with the U.S. SEC at www.sec.gov/edgar.shtml. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of the Company's management at the time they are made, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations change, except as required by law.

Contact:
David Goold
Chief Financial Officer
Phone: [phone] ext. 239
E-mail: [e-mail]

[CHA$E]

Nice move on no news, interesting

[realtorNH]

Forb seems at a crossroads. I am betting they will have one more shot at it.

[realtorNH]

Lay a brother some skin, I bet Forb gets ridden hard by day traders....

[PennyBenny]

Thanks, that's the news what I couldn't find yesterday.

[digitick]

Just look at their news releases. So easy! Ever do any DD?

http://www.marketwatch.com/News/Story/Story.aspx?guid=%7bB3B828F8-D117-4F28-A41D-686A256A669B%7d&...

[PennyBenny]

Why did their stock crash?

[digitick]

Dead board? No bounce-play speculations?

[markets_r_rigged]

Thanks. This seems like a blockbuster, and it's odd that the stock price has basically gone nowhwere. Sales are good; the books look reasonable; they seem to be making the right decisions (for example selling the manufacturing interest). I wonder if the results from FM-VP4 will be the key to future stock price, up or down.

[ypsiCPA]

Reducol is FDA-approved: http://www.reducol.com/s/ProductProfile.asp

Apparently there is no need for separate approval for the margarine spread, or any future products containing Reducol.

[markets_r_rigged]

They are also selling Reducol (margarine spread). From what I read, it's approved and sold in Europe. However, I have purchased it in the US, and was wondering whether this means it is approved in the US as well. Unfortunately, it is impossible to get any useful news on this company - from public information, or even by calling the company and asking. And there always seems to be insider trading prior to any news. Notice the run-up in price this past week prior to the announcement about the sale of the equity in the sterol manufacturing joint venture.

[ypsiCPA]

Cholest-Off is good stuff. I'm still taking it, and (obviously) I'm still here!

[markets_r_rigged]

Is Cholest-off working for you?

[ypsiCPA]

Welcome oldstocks

I take Cholest-Off, as recommended by my dietician. It's nice to see Forbes on the label, I had bought the stock before I was aware of the connection.

[oldstocks]

Forbes Medi-Tech FM-VP24 & FM-VP24 Tuesday 8:00-12:00

American Association of Pharmaceutica Tuesday 8:00 to 12:00!

The links don't work:

PRE-FORMULATION OF PHYTOSTANOL ANALOGUE, FM-VP24 AND ITS EFFECTS ON DIETARY CHOLESTEROL ABSORPTION IN ADULT MALE SPRAGUE DAWLEY RATS

http://abstracts.aapspharmaceutica.com/ExpoAAPS05/CC/forms/attendee/index.aspx?content=sessionInfo&a....

FM-VP4 & FM-VP24
http://abstracts.aapspharmaceutica.com/ExpoAAPS05/CC/forms/attendee/index.aspx?content=speakerInfo&a....

Assessing the lipid lowering activity of Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) in combination with Simvastatin following co-administration to rabbits fed a high fat and cholesterol diet

http://abstracts.aapspharmaceutica.com/ExpoAAPS05/CC/forms/attendee/index.aspx?content=sessionInfo&a....

Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model

http://abstracts.aapspharmaceutica.com/ExpoAAPS05/CC/forms/attendee/index.aspx?content=sessionInfo&a....

Forbes Medi-Tech has started USA phase2 of FM-VP4 drug trial.

Forbes Medi-Tech's Reducol is in Nature Made Cholest-Off that is sold in major stores all across the USA & it is recommened by Pharmacists.

Reducol is in Pirkka yogurt in Europe.

A new product line called Heartfelt is being started in Europe that is going to have Reducol in it.

[ypsiCPA]

Forbes Medi-Tech to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

November 03, 2005 08:00:08 (ET)


VANCOUVER, British Columbia, Nov 03, 2005 (BUSINESS WIRE) -- Forbes Medi-Tech Inc. (FMTI, Trade) today announced that Charles Butt, President and CEO, will be presenting at the upcoming Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York on November 9, 2005.

The Conference will be held at The New York Palace Hotel, and is expected to include approximately 290 presenting companies with an audience of more than 2,000 attendees. The Company's presentation is scheduled for 11:55am Eastern Time.

About Forbes Medi-Tech Inc.

Forbes Medi-Tech Inc. is a life sciences company dedicated to the research, development and commercialization of innovative products for the prevention and treatment of cardiovascular disease. Our vision is to develop and market products along a treatment continuum that cardiovascular disease consumers, healthcare professionals and specialized cardiovascular disease research and healthcare institutions will identify, recommend and seek. Our business strategy is to develop and commercialize proprietary compounds to address the unmet needs of patients within the cardiovascular disease market.

The presentation referred to in this press release is subject to change or cancellation without notice. This News Release contains other forward-looking statements regarding the Company and its business, which statements can be identified by the use of forward-looking terminology such as "vision," "to develop," "will," and "strategy," The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including uncertainty whether the Company will commercialize any products in addition to its food and dietary supplement ingredients currently marketed; research and development risks; uncertainty whether the Company will realize is strategies and vision; intellectual property risks; manufacturing risks and the need to manufacture to regulatory standards; product liability and insurance risks; the effect of competition; and the Company's need for future funding; any of which could cause actual results to vary materially from current results or the Company's anticipated future results. See the Company's reports filed with the Canadian and U.S. securities regulatory authorities from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. The Company assumes no obligation to update the information contained in this News Release.

NASDAQ and the Toronto Stock Exchange have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of t his News Release.

Forbes Medi-Tech Inc. (FMTI, Trade)

SOURCE: Forbes Medi-Tech Inc.


Forbes Medi-Tech Inc.
Darren Seed
Manager, Investor Relations
[phone]
[e-mail]
www.forbesmedi.com
Copyright Business Wire 2005

[ypsiCPA]

Private Placement - New Convertible Preferred

"The preferred shares mature on October 27, 2008, at which time the Company has the option to redeem the shares at their issue price or convert the preferred shares to common shares at 90% of the date of maturity market price."

Could be nasty, holder has incentive to manipulate the market here.

[ypsiCPA]

Now Hiring (thanks for the link Doug)

http://canwest.travidia.com/customad.aspx?ad=2133863

[Dougie31]

Steve Check out this Awesome news.This is as close to inside info as you can get.Heres the news.

http://news.yahoo.com/s/ap/20051020/ap_on_he_me/diabetes_pill_risks

So heres these 2 doctors they Pretty much nix/sqash the Drug FDA was poised to approve.

Dr.Nissen and Dr Topol.(see news above)Dr Nissen is on the advisory board for FDA....hes pretty much advised thm to not aproe merks drug.Dr Topl agreed.

Both these guys have been on the FMTI boards Dr Nissen is currently the scientific director of FMTI's board of drectors.Dr Topol was the lead guy but got busy on something stepped aside and Dr Nissen stepped in.This is so awesome.

FMVP 4 when fully developed will compete head to head with MercksDrugs in the Cholesterol market.FMVP 4 is als oed for Diabetes and weight loss and ANTI plaque.Both the DR's Nissen and Topol kow about FMVP 4and its safety...wich is basically no difference between placebo group and Drug group.

http://www.biospace.com/news_story.aspx?StoryID=15657420&full=1


These 2 doctors who worked For FMTI could discern from mercks drug with sideeffects and FMTI with excellent safety,and Advise FDA to not approve mercks drug wich they were going to approve!!

Thats awesome for FMTI....man as trials go on this stock will go from under2 to 4 or 5 a share or more.......weeeeeeeeeeee

[ypsiCPA]

Welcome Doug. I look forward to having some fun here, as well as making money on FMTI!

[Dougie31]

Hey Mr Steve i own FMTI,JB555 sent me here.Great little company.Great product line.The good thing is its reducol business will pay for its trials for the drug pipeline they have for cardivacular health.Wich is awesome for a small pharma company.

I am truly looking at something wich could turn into a nice sized phama company in next 2 to 3 years,tapping for starters into the 40 billion dollar colesterol market.

Check out this link
http://biz.yahoo.com/bw/050915/155192.html?.v=1

I can show you some other stuff directly related to this link,i must point out though in article above they say that with FMVP 4
that it lowered choleterol more than either could do alone.

Thats totally awesome...i mean that establishes a huge peice of the 40 billion fdollar market......With the bad side effects of the statin drugs...and FMVP 4's excellent safety record.....now the doctors will be able to lower stain usage or increase lower choleterol by marketing the 2 together....so this could also prove a good takeover candidate.

Awesome.....and the shares are a steal.

[iculooking]

FMTI and why its so undervalued...


I know they were guiding at $22 million which was stated in march 2005...but with the june numbers ill bet it's more like 25 million....A huge +....Thats going to be in the news pipeline also, watch......

Also they talk about the 5 year agreement with the european markets, and they have had one product launch then received approval for seven other food catergories. We havent heard about any of these new launches but should anytime or for sure by November....These also are in the news pipeline....

This news pipeline is building for FMTI tremendously.

I peronally think they will be going to $35 million + in Reducol sales in 2006..especially in the European markets. Bear in mind none of these figures take into affect what their cholesteral drug will do to revs when it hits the market.

I think 25% is a given with flashes much higher as more comes out . This truly is a new novel drug that Merck already wants a peice of. By year end this should be trading at $10 or higher imo.


Take a look at this bullish 3 candle formation.

http://stockcharts.com/def/servlet/SC.web?c=FMTI

Its a Low floater (3 M) too, that could double this week, you might want to get some. Nasdaq stock trading at $1.90 that has been beaten down the last few days because their big plant is in Texas, but now the hurricane missed it and all is well, which means that the shorts will be and are covering.

Plus, this week they will get approval of their news cholesteral phase 2 drug that puts them one step away from being a major player in the $50 BILLION cholesteral market, next to Merck. In fact they are developing a partner ship with Merck. Chart looks great (golden cross soon), think of this news and the fact it hasnt ran up at all so far it very well could hit $4-$5 next week.